Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digoxin, Furosemide, Metformin, and Rosuvastatin Cocktail Bioavailability Study
NCT02231931Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2014
- Primary completion
- Jan 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of digoxin, furosemide, metformin and rosuvastatin in heart failure (HF), Atrial fibrillation (AFib), edema and 3 more (7 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to the last quantifiable data point at 96 hours and Maximum measured concentration in plasma at 96 hours. Started Sep 2014; status: completed.
02
Drugs
digoxinfurosemidemetforminrosuvastatin
03
Conditions
heart failure (HF)Atrial fibrillation (AFib)edemahypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02231931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231931.